61 results
8-K
EX-99.1
CGTX
Cognition Therapeutics Inc
26 Mar 24
Cognition Therapeutics Reports Year End 2023 Financial Results and Provides Business Update
7:12am
of The Private Securities Litigation Reform Act of 1995. All statements contained in this press release, other than statements of historical facts
8-K
EX-1.1
CGTX
Cognition Therapeutics Inc
13 Mar 24
Entry into a Material Definitive Agreement
4:07pm
policy considerations in respect thereof.
(v) No Litigation. There is no action, suit, proceeding, inquiry, arbitration, investigation, litigation … , criminal or governmental litigation or proceeding, (ii) if not given in the past, might have had a Material Adverse Effect or (iii) if not continued
424B5
CGTX
Cognition Therapeutics Inc
13 Mar 24
Prospectus supplement for primary offering
4:04pm
;
additions or departures of key personnel;
intellectual property, product liability, or other litigation against us; and
S-8
general economic, industry … -looking statements are intended to be covered by the safe harbor for forward-looking statements provided by the Private Securities Litigation Reform
424B5
jy3l8irdnpz868w
11 Mar 24
Prospectus supplement for primary offering
4:06pm
424B4
pg5v59132tnm
8 Jan 24
Prospectus supplement with pricing info
4:11pm
8-K
EX-99.1
d20qa675v
4 Jan 24
Other Events
4:21pm
8-K
EX-99.1
jwcxh
2 Nov 23
Cognition Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
7:41am
8-K
EX-99.1
kitcpb 9v9kbxv75lu
12 Sep 23
Other Events
7:00am
8-K
EX-99.1
ig2f n1wrm182
24 Aug 23
Regulation FD Disclosure
7:00am
8-K
EX-99.1
2v9il2k ta4o
8 Aug 23
Cognition Therapeutics Reports Second Quarter 2023 Financial Results and Business Update
7:05am
8-K
EX-99.1
eercjts6tnh4
28 Jun 23
Cognition Therapeutics Announces Positive Topline Results for CT1812 Phase 2 SEQUEL Study for Mild-to-Moderate Alzheimer’s Disease
7:27am
8-K
EX-99.2
5ma4 hkr5t22
28 Jun 23
Cognition Therapeutics Announces Positive Topline Results for CT1812 Phase 2 SEQUEL Study for Mild-to-Moderate Alzheimer’s Disease
7:27am
8-K
EX-99.1
svr n265p8ni
4 May 23
Cognition Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
4:06pm
8-K
EX-10.1
1fu7e6ky
1 May 23
Departure of Directors or Certain Officers
7:30am